ArticleLeukemia2013
Towards effective and safe immunotherapy after allogeneic stem cell transplantation: identification of hematopoietic-specific minor histocompatibility antigen UTA2-1.
Article in Leukemia, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 28 citations in OpenAlex.
- Efficacy of host-dendritic cell vaccinations with or without minor histocompatibility antigen loading, combined with donor lymphocyte infusion in multiple myeloma patients.Bone marrow transplantation · 2017Trial
- Resf1 is a compound G4 quadruplex-associated tumor suppressor for triple negative breast cancer.PLoS genetics · 2024Article
- Clinical Perspectives of Non-Coding RNA in Oral Inflammatory Diseases and Neuropathic Pain: A Narrative Review.International journal of molecular sciences · 2022Review
- Personal tumor antigens in blood malignancies: genomics-directed identification and targeting.The Journal of clinical investigation · 2020Review
- The Connection Between Minor H Antigens and Neoantigens and the Missing Link in Their Prediction.Frontiers in immunology · 2020Review
- Rapid Multiplex Genotyping of 20 HLA-AFrontiers in immunology · 2019Article
- Computational modeling and confirmation of leukemia-associated minor histocompatibility antigens.Blood advances · 2018Article
- Minor histocompatibility Ags: identification strategies, clinical results and translational perspectives.Bone marrow transplantation · 2016Review
- Autosomal Minor Histocompatibility Antigens: How Genetic Variants Create Diversity in Immune Targets.Frontiers in immunology · 2016Review
- Strategies for the identification of T cell-recognized tumor antigens in hematological malignancies for improved graft-versus-tumor responses after allogeneic blood and marrow transplantation.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2015Review
- Effect of mismatching for mHA UTA2-1 on clinical outcome after HLA-identical sibling donor allo-SCT.Bone marrow transplantation · 2015Article
- Identification of minor histocompatibility antigens based on the 1000 Genomes Project.Haematologica · 2014Article
- Altered peptide ligands revisited: vaccine design through chemically modified HLA-A2-restricted T cell epitopes.Journal of immunology (Baltimore, Md. : 1950) · 2014Article
- Immunotherapeutic approaches to treat multiple myeloma.Human vaccines & immunotherapeutics · 2014Review
- Minor histocompatibility antigens and the maternal immune response to the fetus during pregnancy.American journal of reproductive immunology (New York, N.Y. : 1989) · 2013Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Donor T cells directed at hematopoietic system-specific minor histocompatibility antigens (mHags) are considered important cellular tools to induce therapeutic graft-versus-tumor (GvT) effects with low risk of graft-versus-host disease after allogeneic stem cell transplantation. To enable the clinical evaluation of the concept of mHag-based immunotherapy and subsequent broad implementation, the identification of more hematopoietic mHags with broad applicability is imperative. Here we describe novel mHag UTA2-1 with ideal characteristics for this purpose. We identified this antigen using genome-wide zygosity-genotype correlation analysis of a mHag-specific CD8(+) cytotoxic T lymphocyte (CTL) clone derived from a multiple myeloma patient who achieved a long-lasting complete remission after donor lymphocyte infusion from an human leukocyte antigen (HLA)-matched sibling. UTA2-1 is a polymorphic peptide presented by the common HLA molecule HLA-A*02:01, which is encoded by the bi-allelic hematopoietic-specific gene C12orf35. Tetramer analyses demonstrated an expansion of UTA2-1-directed T cells in patient blood samples after several donor T-cell infusions that mediated clinical GvT responses. More importantly, UTA2-1-specific CTL effectively lysed mHag(+) hematopoietic cells, including patient myeloma cells, without affecting non-hematopoietic cells. Thus, with the capacity to induce relevant immunotherapeutic CTLs, it's HLA-A*02 restriction and equally balanced phenotype frequency, UTA2-1 is a highly valuable mHag to facilitate clinical application of mHag-based immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.